From a pharmacoeconomic point of view, it might thus be appropriate to withdraw MOH patients from overuse, not only at the start of any prophylactic migraine treatment, but also before considering 3rd or 4th line therapies with expensive drugs like anti-CGRP/rec mAbs or BoNT-A, which is currently not requested by most reimbursement policies. This evidence concerns the gene CALCA and migraine disorder.